Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • 2019 Seclusion and Restraint: Assessment and Risk Mitigation

    Contains 6 Component(s), Includes Credits

    Presenters: Diane Allen, DNP, RN-BC, NEA-BC, FACHE; Stephanie Bradley, MSN, APRN-BC; Todd Lauster, BA, RN-BC Contributing APNA Member Nurses: Gisela Catano-Mahoney, MEd, RN-BC; Sandra Gary, BSN, RN-BC; Justin Souther, RN-BC 1.0 contact hours

    2019 Seclusion and Restraint: Assessment and Risk Mitigation

    Following the guidelines of the updated and revised APNA position statement and standards of Seclusion and Restraint, this session was developed in hopes of reminding nurses of the risks associated with seclusion and restraint, and the ability for nurses to mitigate these risks and recognize the readiness for release.

    Presenters: Diane Allen, DNP, RN-BC, NEA-BC, FACHE; Stephanie Bradley, MSN, APRN-BC; Todd Lauster, BA, RN-BC

    Contributing APNA Member Nurses: Gisela Catano-Mahoney, MEd, RN-BC; Sandra Gary, BSN, RN-BC; Justin Souther, RN-BC

    Disclosures: The presenters and planners have no conflict of interest or commercial support to disclose. Off-label use of medications will not be discussed during this presentation.

    Session Length: 42 minutes

    Target Audience: RN, APRN

    Learning Outcomes:
    Upon completion of this presentation, the participant will be able to:
    1. Identify at least two risks of harm during seclusion and restraint.
    2. Describe two interventions to mitigate risks of harm during seclusion and restraint.
    3. Recognize indicators of readiness for discontinuation of seclusion and restraint. 

    Keywords: Seclusion, Restraint, Safety

    Continuing Nursing Education
    1.0 contact hours.
    * In order to receive contact hours, you must: Listen to the entire session, complete an evaluation, and earn a passing score on the post test before the expiration date. You will have 5 tries to earn a passing score on the post test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.


    Release Date:  September 18, 2019
    The contact hours for this session expire:  September 30, 2022

  • 303-19: Pharmacological Management of Alzheimer’s Disease and Other Neurocognitive Disorders

    Contains 5 Component(s), Includes Credits

    Presenter: Pamela Z. Cacchione, PhD, CRNP, BC, FGSA, FAAN 1.5 pharmacology contact hours

    303-19:  Pharmacological Management of Alzheimer’s Disease and Other Neurocognitive Disorders 

    Delve into key considerations for making pharmacologic decisions across Alzheimer’s disease and other neurocognitive disorders. Use a holistic methodology to ensure patient-centered care that encompasses family and support factors.


    Presenter:
      Pamela Z. Cacchione, PhD, CRNP, BC, FGSA, FAAN

    Disclosures:  The speaker has indicated a significant financial interest or other affiliation with Clinical Nursing Research (royalties). Off-label uses will not be discussed during this presentation. The activity planners have no conflicts of interest to disclose.


    Session Length:
      1 hour 27 minutes

    Target Audience:  RN, APRN


    Learning Outcomes:
    Upon completion of this presentation, the participant will be able to:

    1. Identify appropriate medications for persons with Alzheimer’s disease and other neurocognitive disorders.
    2. Discuss informed consent from responsible parties for the use of medications in Alzheimer’s disease and other neurocognitive disorders.

    Keywords:  Psychopharmacology, Alzheimer’s Disease


    Continuing Nursing Education:
    1.5 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.


    Originally Presented:
    APNA 17th Annual Clinical Psychopharmacology Institute
    Louisville, KY
    Sunday, June 9, 2019
    12:15pm - 1:45pm


    The contact hours for this session expire:  June 30, 2021

  • 301-19: From Immediate Release to Long Acting: Drug Delivery Systems - What Do They Mean & Why Do They Matter?

    Contains 5 Component(s), Includes Credits

    Presenter: Laura G. Leahy, DrNP, APRN, FAANP 1.5 pharmacology contact hours

    301-19:  From Immediate Release to Long Acting: Drug Delivery Systems - What Do They Mean & Why Do They Matter?

    Transform your clinical approach to the use of long acting injectables, considering them as a strategy for consistency in dosing. Understand the neurobiology behind this first line treatment option.


    Presenter:
      Laura G. Leahy, DrNP, APRN, FAANP

    Disclosures:  The speaker has indicated a significant financial interest or other affiliation with Alkermes, NEOS Therapeutics, Genomind, and Otsuka (honorarium). She receives royalties from American Psychiatric Publishing, Inc. Off-label uses will be discussed during this presentation. The activity planners have no conflicts of interest to disclose.

    Session Length:  1 hour 24 minutes

    Target Audience:  RN, APRN


    Learning Outcomes:
    Upon completion of this presentation, the participant will be able to:

    1. Differentiate between 3 unique drug delivery systems. 
    2. Describe 3 reasons why drug delivery systems may influence treatment outcomes.

    Keywords:  Psychopharmacology, Prescribing, Drug Delivery Systems


    Continuing Nursing Education:
    1.5 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.


    Originally Presented
    APNA 17th Annual Clinical Psychopharmacology Institute
    Louisville, KY
    Sunday, June 9, 2019
    8:00am - 9:30am


    The contact hours for this session expire:  June 30, 2021

  • 304-19: Neurobiologic Aspects of Trauma

    Contains 5 Component(s), Includes Credits

    Presenter: Elizabeth M. Fitelson, M.D. 1.5 pharmacology contact hours

    304-19: Neurobiologic Aspect of Trauma

    Appreciate how the phases of intimate partner violence and/or sexual assault impact prescribing practices. Link that knowledge to the neurobiological aspects of trauma and how medications address this population's needs on several levels.


    Presenter:
      Elizabeth M. Fitelson, M.D.

    Disclosures:  The presenter and planners have no conflict of interest or commercial support to disclose. Off-label uses will be discussed during this presentation. The activity planners have no conflicts of interest to disclose.


    Session Length:
      1 hour 29 minutes

    Target Audience:  RN, APRN


    Learning Outcomes:
    Upon completion of this presentation, the participant will be able to:

    1. Identify how trauma impacts neural circuitry, and how this in turn leads to higher burden of psychopathology.
    2. Explore effective strategies for pharmacologic treatment of PTSD and related comorbidity.

    Keywords:  Psychopharmacology, Trauma


    Continuing Nursing Education:
    1.5 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.


    Originally Presented
    APNA 17th Annual Clinical Psychopharmacology Institute
    Louisville, KY
    Sunday, June 9, 2019
    2:00pm - 3:30pm


    The contact hours for this session expire:  June 30, 2021

  • 302-19: Gabapentin Use & Misuse

    Contains 5 Component(s), Includes Credits

    Presenter: Christian J. Teter, PharmD, BCPP, RPh 1.25 pharmacology contact hours

    302-19:  Gabapentin Use & Misuse

    Consider Gabapentin in the light of current practice, to understand it’s use and misuse. Consider the implications of gabapentin misuse for clinical practice and future research.

    Presenter:  Christian J. Teter, PharmD, BCPP, RPh

    Disclosures: The speaker has indicated a significant financial interest or other affiliation with Marblehead NeuroPsychiatric Rx, LLC. Off-label uses will be discussed during this presentation. The activity planners have no conflicts of interest to disclose.

    Session Length:  1 hour 20 minutes

    Target Audience:  RN, APRN


    Learning Outcomes:
    Upon completion of this presentation, the participant will be able to:

    1. Identify the scope (e.g., prevalence, risk factors, motives, outcomes) of gabapentin misuse.
    2. Describe the implications of gabapentin misuse for clinical practice and future research.

    Keywords:  Psychopharmacology, Drug Diversion, Gabapentin


    Continuing Nursing Education:
    1.25 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.


    Originally Presented
    17th Annual Clinical Psychopharmacology Institute
    Louisville, KY
    Sunday, June 9, 2019
    9:45am - 11:15am


    The contact hours for this session expire:  June 30, 2021

  • 202-19: Complex Topics in Substance Use: Drug Adulterants, Treatment Transitions, & Pregnancy

    Contains 5 Component(s), Includes Credits

    Presenter: Matt Tierney, ANP, PMHNP, FAAN 1.5 pharmacology contact hours

    202-19: Complex Topics in Substance Use: Drug Adulterants, Treatment Transitions, & Pregnancy

    Examine hot topics in substance use disorders to gain an understanding of current and emerging needs, including: adulterants in the illicit drug supply and related harm reduction strategies; transitions in medication treatment for opioid use; and treatment of opioid use disorder during pregnancy and postpartum period.


    Presenter:
      Matt Tierney, ANP, PMHNP, FAAN

    Disclosures:  The speaker has indicated a significant financial interest or other affiliation with Johnson & Johnson, and participates in the Nursing Advisory Council on Opioids. Off-label uses will not be discussed during this presentation. The activity planners have no conflicts of interest to disclose.


    Session Length:  1 hour 27 minutes

    Target Audience:  RN, APRN


    Learning Outcomes:
    Upon completion of this presentation, the participant will be able to:

    1. Utilize several strategies to address the numerous dangers associated with adulterants in illicit drug supplies.
    2. Translate evidence-based knowledge and best-practice recommendations to assist patients in OUD treatment transition from methadone to buprenorphine.

    Keywords:  Substance Use, Opioids, Psychopharmacology


    Continuing Nursing Education:
    1.5 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.


    Originally Presented

    APNA 17th Annual Clinical Psychopharmacology Institute
    Louisville, KY
    Saturday, June 8, 2019
    9:45am - 11:15am


    The contact hours for this session expire:  June 30, 2021

  • 203-19: The Art of Deprescribing: An Evidence-Based Approach to Understanding Who is the Right Patient, When is the Right Time, and How to Taper Medication?

    Contains 5 Component(s), Includes Credits

    Presenter: Dawn Vanderhoef, PhD, DNP, PMHNP-BC, FAANP 1.5 pharmacology contact hours

    203-19:  The Art of Deprescribing: An Evidence-Based Approach to Understanding Who is the Right Patient, When is the Right Time, and How to Taper Medication?

    Get the current evidence-based practices for weaning patients off medications safely and effectively. Understand how these processes and considerations fit into the wellness approach you take in providing care.

    Presenter:  Dawn Vanderhoef, PhD, DNP, PMHNP-BC, FAANP

    Disclosures:  The speaker has indicated a significant financial interest or other affiliation with Neurocrine Biosciences (advisory panel member & honorarium). Off-label uses will be discussed during this presentation. The activity planners have no conflicts of interest to disclose.


    Session Length:
      1 hour 22 minutes

    Target Audience:  RN, APRN


    Learning Outcomes:
    Upon completion of this presentation, the participant will be able to:

    1. Apply an evidence-based approach to identify patients who are candidates for deprescribing.
    2. Describe best practices for deprescribing psychotropic medication.

    Keywords:  Deprescribing, Tapering, Psychopharmacology


    Continuing Nursing Education:
    1.5 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.


    Originally Presented
    APNA 17th Annual Clinical Psychopharmacology Institute
    Louisville, KY
    Saturday, June 8, 2019
    1:45pm - 3:15pm


    The contact hours for this session expire:  June 30, 2021

  • Motivational Interviewing

    Contains 13 Component(s), Includes Credits

    Presenter: Carol Essenmacher, DNP, C-TTS 3.0 contact hours

    Motivational Interviewing

    Motivational Interviewing (MI) is a person-centered form of guiding to elicit and strengthen motivation for change. Motivation for change occurs when people perceive a mismatch between “where they are and where they want to be.” When clients recognize that their current behaviors place them in conflict with (are discrepant with) their values or interfere with accomplishment of self-identified goals, they are more likely to experience increased motivation to make important life changes. In MI, the goal is to help clients to become aware of how current behaviors may lead them away from, rather than toward, their important goals.

    This three-part presentation is designed to help you learn Motivational Interviewing and how to apply it in your practice. It discusses the core principles of Motivational Interviewing and provides case studies for practice. It takes continued practice to deepen your effectiveness in applying MI skills to your area of practice. After you complete this presentation, we encourage you to plan for further skill development in MI!


    Presenter:
     Carol Essenmacher, DNP, C-TTS
    Contributing Faculty: Susan W. Blaakman, PhD, RN, PMHNP-BC; Susie Adams, PhD, PMHNP, FAANP, FAAN; Ann Bispo, MSN, APRN, PMHCNS-BC

    Disclosures: The presenters and planners have no conflict of interest or commercial support to disclose. Off-label use of medications will not be discussed during this presentation.


    Session Length:
     3 hours

    Target Audience: RN, APRN


    Learning Outcomes:
    Upon completion of this presentation, the participant will be able to:

    1. Verbalize an understanding of the history and significance of Motivational Interviewing (MI).
    2. Illustrate three Motivational Interviewing skills to elicit change talk, and support behavior change.
    3. Identify three stage-specific interventions to motivate behavior change.

    Keywords: MI, Motivational Interviewing, Behavior Change


    Continuing Nursing Education:
    3.0 contact hours. *In order to receive contact hours, you must: Listen to presentation, earn a passing score on the post-tests, and complete an evaluation before the expiration date. You will have 5 tries to correctly answer the questions on the post-tests and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed. Partial credit will not be awarded.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

    The contact hours for this session expire: September 30, 2022

  • W102-19: Psychopharmacology for Persons with Alzheimer's and Other Dementias

    Contains 5 Component(s), Includes Credits

    Presenter: Pierre Tariot, MD 1.5 pharmacology contact hours

    W102-19:  Psychopharmacology for Persons with Alzheimer's and Other Dementias

    This session provides clarity on the varying types of dementias known to occur. Current research and treatment guidelines for Alzheimer’s disease are presented in detail.


    Presenter:
      Pierre Tariot, MD

    Disclosures:  The speaker has indicated a significant financial interest or other affiliation with the following: Consulting fees: Acadia, Abbott Laboratories, AbbVie, AC Immune, Auspex, Boehringer-Ingelheim, Brain Test Inc., California Pacific Medical Center, Chase Pharmaceuticals, Eisai, GliaCure, Insys Therapeutics, Pfizer, T3D; Consulting fees and research support: AstraZeneca, Avanir, Lilly, Lundbeck, Merck & Co., Roche, Takeda; Research support only: Amgen, Avid, Biogen, Functional Neuromodulation (f(nm)), GE, Genentech, Novartis; Other research support: NIA, Arizona Department of Health Services, Alzheimer's Association, Banner Alzheimer’s Foundation, FBRI, GHR, Nomis Foundation, Flinn Foundation, Geoffrey Beene Foundation; Patents: Contributor to a patent owned by the University of Rochester, “Biomarkers of Alzheimer’s Disease.”; Stocks: Owner of stock options in Adamas Pharmaceuticals. Off-label use of medications will be discussed during this presentation. The activity planners have no conflicts of interest to disclose.


    Session Length:
      1 hour 26 minutes

    Target Audience:  APRN


    Learning Outcomes:
    Upon completion of this presentation, the participant will be able to:

    1. Explore a systematic approach to differential diagnosis of the dementias, the deployment of cognitive enhancers for Alzheimer’s disease, and evaluate both non-pharmacological and pharmacological management of neuropsychiatric features of dementia.
    2. Discuss the emerging drug treatment landscape for treatment and prevention of dementia.

    Keywords:  Psychopharmacology, Alzheimer’s, Dementia


    Continuing Nursing Education:
    1.5 pharmacology contact hours.  *In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.


    Originally Presented
    APNA Clinical Psychopharmacology Institute - West
    San Diego, CA
    Saturday, March 16, 2019
    1:45pm – 3:15pm


    The contact hours for this session expire:  June 30, 2021

  • W103-19: Ethical Decision-Making in Mental Health & Psychopharmacology

    Product not yet rated Contains 5 Component(s), Includes Credits

    Presenters: Mindy B. Zeitzer, PhD, MBE, RN; Barbara Limandri, PhD, PMHCNS-BC; Barbara Warren, PhD, RN, PMHCNS-BC, FNAP, FAAN 1.25 contact hours

    W103-19:  Ethical Decision-Making in Mental Health & Psychopharmacology

    In this session the main principles of ethics are described and applied to common issues encountered when prescribing psychopharmacologic medications. Those ethical principles are then applied to a brief case study, in a discussion format with two practicing PMH APRNs.


    Presenters:
      Mindy B. Zeitzer, PhD, MBE, RN; Barbara Limandri, PhD, PMHCNS-BC; Barbara Warren, PhD, RN, PMHCNS-BC, FNAP, FAAN

    Disclosures:  The presenters and planners have no conflict of interest or commercial support to disclose.  Off-label use of medications will not be discussed during this presentation.


    Session Length:
      1 hour 16 minutes

    Target Audience:  APRN


    Learning Outcomes:
    Upon completion of this presentation, the participant will be able to:

    1. Explain the difference between ethical decision-making and clinical decision-making.
    2. Identify when ethical reasoning needs to occur and what ethical principles are applicable.

    Keywords:  Practice, Ethics, Prescribing


    Continuing Nursing Education:
    1.25 contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

    The American Psychiatric Nurses Association is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.


    Originally Presented
    APNA Clinical Psychopharmacology Institute - West
    San Diego, CA
    Saturday, March 16, 2019
    3:30pm – 5:00pm


    The contact hours for this session expire:  June 30, 2021